The scale of the problem is considerable. Breast cancer accounted for approximately 2.308 million new cases worldwide in 2022, representing 11.6 percent of all new cancer diagnoses and making it the second most common cancer globally. Chemotherapy remains a cornerstone of treatment for early-stage disease, but its toxicities—ranging from severe neutropenia to peripheral neuropathy—can force dose reductions, treatment interruptions, or complete discontinuation, ultimately compromising prognosis and quality of life.

The review, led by researchers at The First Affiliated Hospital of Jinzhou Medical University in China, synthesizes evidence on how body composition indicators relate to chemotherapy toxicity. The authors trace the evolution of assessment methods from crude anthropometric surrogates—such as the five percent weight-loss threshold once used to mark cachexia in the 1970s—to today’s sophisticated imaging tools. Computed tomography, magnetic resonance imaging, dual-energy X-ray absorptiometry (DXA), and bioelectrical impedance analysis (BIA) now allow clinicians to quantify skeletal muscle, visceral fat, subcutaneous fat, and muscle quality with remarkable precision, and artificial intelligence is increasingly automating these analyses.

Central to the discussion is the distinction between lean body mass and fat-free mass, terms that are chemically similar but historically defined differently—lean body mass includes polar lipids, while fat-free mass does not. The authors recommend prioritizing fat-free mass in research to improve scientific rigor. They also highlight the third lumbar vertebra skeletal muscle index (L3-SMI), calculated from a single CT slice as skeletal muscle area at L3 divided by height squared, which was first reported in 2008 as an independent predictor of chemotherapy toxicity. Notably, DXA-derived appendicular lean mass indices and CT-based L3-SMI correlate only moderately (r = 0.66, p < 0.001), meaning the two metrics are not directly interchangeable—a source of ongoing confusion in the literature.

The mechanistic story is where the review becomes particularly compelling. Muscle is highly vascularized and metabolically active, so patients with greater lean mass tend to metabolize and clear drugs more efficiently. Pharmacokinetic studies bear this out: each additional kilogram of lean body mass increased doxorubicin clearance by roughly 19 percent in an exploratory study, and lower muscle mass was associated with reduced volume of distribution and higher peak plasma concentrations of paclitaxel. Low lean mass can also reduce creatinine production, causing the Cockcroft-Gault formula to overestimate renal function—a hazard flagged by a creatinine clearance to glomerular filtration rate ratio of 1.23 as a warning threshold for carboplatin overdose and severe thrombocytopenia.

Fat tells a different, sometimes paradoxical story. Lipophilic agents such as paclitaxel and docetaxel distribute into adipose compartments, while hydrophilic drugs like fluoruracil and cyclophosphamide prefer water-rich lean tissue. Visceral fat volume was positively correlated with doxorubicin exposure (r² = 0.324, P < 0.001) and grade 4 leukopenia in Asian breast cancer patients. Experimental work suggests adipocytes can increase anthracycline levels by 30 percent by upregulating CBR1 and AKR metabolic enzymes, sustaining the release of toxic metabolites. Visceral fat-derived free fatty acids also reach the liver through the portal circulation, potentially inducing hepatic steatosis and impairing drug metabolism—liver attenuation on CT, inversely related to fat content, predicted epirubicin exposure in one analysis.

The clinical correlations are striking. In early-stage breast cancer patients, higher fat mass increased the risk of toxicity-induced modification of treatment—dose reductions, interruptions, cessation, or regimen changes—while higher relative lean mass reduced that risk. Obese patients (BMI ≥ 30 kg/m²) experienced docetaxel dose reductions at 18 percent versus 5 percent in nonobese patients (p = 0.008), along with lower pathological complete response rates and shorter disease-free survival. Sarcopenia, which affects an estimated 40 to 45 percent of breast cancer patients, independently predicted severe toxicity: sarcopenic patients receiving epirubicin-cyclophosphamide experienced severe laboratory adverse events at 70 percent versus 22.2 percent (OR 7.9, p = 0.004). Myosteatosis—fat infiltration within muscle, visible as lower Hounsfield units on CT—was associated with reduced relative dose intensity and with dose reductions, early treatment interruption, and hospitalization.

Perhaps the most alarming phenotype is sarcopenic obesity, the coexistence of excessive adiposity with reduced muscle mass and impaired function, as defined by the ESPEN-EASO consensus. In early-stage breast cancer patients receiving anthracycline and taxane chemotherapy, sarcopenic obesity independently predicted severe toxicity, tripling the risk of grade 3–4 hematological toxicity and raising the risk of neutropenia 3.5-fold. Prevalence estimates vary widely—from 0.8 to 22.3 percent in general populations—partly because diagnostic thresholds remain inconsistent, with more than 14 sarcopenia cutoffs reported across oncology studies.

The review does not shy away from the field’s contradictions. Adipose tissue can exert bidirectional effects: in one study of 120 patients receiving neoadjuvant chemotherapy, higher fat percentage correlated with reduced neurotoxicity risk, though no significant interaction appeared in platinum-containing regimens. Chemotherapy itself alters body composition over time, and most studies rely only on baseline measurements, potentially underestimating true toxicity risk. The authors also point to the LEANOX randomized controlled trial as proof of concept: lean body mass-based oxaliplatin dosing at 3.09 mg/kg increased the proportion of patients free of grade ≥ 2 peripheral neurotoxicity from 42.1 to 67.2 percent, without compromising long-term survival—evidence that composition-guided dosing is clinically practicable, at least for some drugs.

Looking forward, the authors call for regimen-specific pharmacokinetic modeling across anthracyclines, taxanes, and platinum agents; risk stratification that integrates breast cancer subtypes with visceral-to-subcutaneous fat ratios and muscle indices; prospective trials of nutritional optimization and resistance training in high-risk patients; and international consensus on definitions and cutoffs, potentially enriched with multi-omics biomarkers. They suggest DXA, a low-radiation whole-body scan, could eventually replace CT for routine body composition assessment in early cancer, where L3-level CT scans are not standard. Until prospective, breast cancer-specific studies validate these approaches, body surface area dosing will remain the norm—but the writing is on the wall, and it is written in muscle and fat.

Subject of Research: The relationship between body composition and chemotherapy-related toxicity in early-stage breast cancer

Article Title: Body composition and chemotherapy-related toxicities in early-stage breast cancer: implications for personalized treatment strategies

Article References: Body composition and chemotherapy-related toxicities in early-stage breast cancer: implications for personalized treatment strategies. (n.d.). https://doi.org/10.1007/s44178-026-00287-4

Image Credits: AI Generated

DOI: 10.1007/s44178-026-00287-4

Keywords: breast cancer, body composition, chemotherapy toxicity, sarcopenia, sarcopenic obesity, lean body mass, visceral fat, myosteatosis, pharmacokinetics, personalized dosing, DXA, CT imaging

Breast cancer remains the most prevalent form of cancer among women worldwide and constitutes more than 15% of all new cancer diagnoses in the United States alone. The pathological entities DCIS and LCIS are characterized by abnormal cells confined respectively within the breast ducts and lobules, and while non-invasive themselves, have been strongly implicated as precursors to invasive breast cancer. However, clinicians have long grappled with the challenge of discerning which cases of DCIS and LCIS will progress to invasive disease, complicating treatment decisions and often leading to overtreatment or undertreatment.

The PRS₃₁₃ test quantifies breast cancer risk by aggregating the effects of 313 single-nucleotide polymorphisms (SNPs) that have previously been associated with breast cancer susceptibility. These genetic markers collectively provide a polygenic risk profile that reflects an individual’s inherited predisposition. Prior validation of PRS₃₁₃ in populations of women with no prior cancer history demonstrated its capacity to stratify breast cancer risk effectively. This study, relentlessly spearheaded by Jasmine Timbres and senior author Professor Elinor J. Sawyer, positions PRS₃₁₃ as a potentially transformative tool for risk stratification specifically in patients already diagnosed with DCIS or LCIS.

To rigorously evaluate the predictive utility of PRS₃₁₃ in in situ breast disease, the research team delved into comprehensive datasets from two major UK-based cohorts — the ICICLE (ductal carcinoma in situ) and GLACIER (lobular carcinoma in situ) studies. Cumulatively, these databases provided genetic and longitudinal clinical follow-up information for 2,169 women with DCIS and 185 women with LCIS. Applying sophisticated statistical models, the team analyzed the association between patients’ PRS₃₁₃ scores and their subsequent risk of developing invasive breast cancer over time.

The results illuminate critical distinctions in risk profiles based on PRS₃₁₃ quartiles and anatomical tumor locations. Among women with DCIS, those within the highest PRS₃₁₃ quartile exhibited a twofold increase in the likelihood of developing contralateral breast cancer—the manifestation of invasive disease in the breast opposite the site of the initial in situ lesion. Interestingly, the predictive value of PRS₃₁₃ did not extend significantly to ipsilateral breast cancer in DCIS patients, an observation that underscores the complex biology and progression pathways of breast neoplasms.

Conversely, the data revealed a strong dose-response relationship in LCIS patients: as PRS₃₁₃ scores increased, so did the risk of ipsilateral invasive breast cancer, with risk more than doubling per unit increase in the score. These findings suggest that the genetic architecture captured by PRS₃₁₃ may differentially influence localized tumor progression depending on in situ tumor subtype, potentially guiding subtype-specific surveillance and intervention strategies.

A notable aspect of the study is the interaction between family history and polygenic risk scores. Women carrying a familial predisposition to breast cancer exhibited a markedly amplified risk associated with higher PRS₃₁₃ values, surpassing a threefold increase for ipsilateral cancer following LCIS. Remarkably, this risk escalated to fourfold among women without prior mastectomy or radiotherapy, highlighting the importance of integrating genetic risk scores with familial information and treatment history to refine prognostication.

Professor Sawyer elaborated on the clinical implications, emphasizing that LCIS, traditionally considered lower risk than DCIS and often managed conservatively without surgery or hormone therapy, may warrant reconsideration for more aggressive treatment in patients with elevated polygenic risk and familial background. Such tailored therapies could significantly reduce progression to invasive cancer, improving patient outcomes and quality of life.

The study pioneers a paradigm shift in breast cancer risk assessment by advocating a comprehensive approach that transcends histopathological evaluation. As Timbres elucidates, employing PRS₃₁₃ alongside traditional diagnostics offers a nuanced risk profile that empowers women with DCIS or LCIS to make more informed choices regarding their management options, balancing efficacy and potential overtreatment.

Despite promising insights, the study acknowledges inherent limitations. The PRS₃₁₃ was originally optimized for invasive breast cancer risk prediction, thus it may not capture genetic variants specifically implicated in in situ lesions that remain to be discovered. Additionally, the limited LCIS sample size constrains the statistical power to detect more subtle associations, warranting validation in larger, more diverse populations.

Funding support for the research was provided by Breast Cancer Now, Cancer Research UK, and the Biomedical Research Centre at Guy’s and St Thomas’ NHS Foundation Trust and King’s College London. Both lead and senior authors report no conflicts of interest, underscoring the study’s integrity and scientific rigor.

These compelling findings herald a new frontier in precision oncology, where polygenic risk scoring complements existing histological and clinical parameters to tailor breast cancer prevention and treatment strategies. As further validation and technological advancements unfold, integrating PRS₃₁₃ into clinical workflows may revolutionize how clinicians assess risk and personalize care for women with in situ breast disease, ultimately mitigating the burden of invasive breast cancer on a global scale.

Subject of Research: Breast cancer risk prediction using a 313-SNP polygenic risk score in patients with ductal and lobular carcinoma in situ

Article Title: Breast Cancer Polygenic Risk Score Associated With Outcomes After In Situ Breast Disease

News Publication Date: 1-Oct-2025

Web References:

• Cancer Epidemiology, Biomarkers & Prevention
• ICICLE Study
• GLACIER Study
• PRS₃₁₃ Validation Study

References: DOI: 10.1158/1055-9965.EPI-25-0529

Keywords: Breast cancer, Polygenic risk score, DCIS, LCIS, Genetic risk, Cancer epidemiology, Personalized medicine, In situ breast disease